Posted by Michael Wonder on 11 Apr 2024
NICE issues final draft guidance for use of remdesivir and also for tixagevimab-cilgavimab (Evusheld) for treatment of COVID-19
9 April 2024 - Final draft guidance for remdesivir and for tixagevimab with cilgavimab has been published by NICE.
The SMC has had direct input into the decision-making committee that produced the final draft guidance.
The final draft guidance recommends remdesivir as an option for treating COVID-19 in hospitals in specific patient groups.
